Benjamin Seeliger1, Michael Döbler2, Sascha David3,4, Christian Bode5, Robert Friedrich1, Klaus Stahl6, Christian Kühn7, Johann Bauersachs8, Folkert Steinhagen2, Stefan F Ehrentraut2, Jens-Christian Schewe2, Christian Putensen2, Tobias Welte1, Marius M Hoeper1, Andreas Tiede9. 1. Department of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-Stage and Obstructive Lung Disease (BREATH), German Lung Research Center (DZL), Hannover, Germany. 2. Department of Anaesthesiology and Critical Care Medicine, University Hospital Bonn, Bonn, Germany. 3. Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. David.sascha@mh-hannover.de. 4. Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland. David.sascha@mh-hannover.de. 5. Department of Anaesthesiology and Critical Care Medicine, University Hospital Bonn, Bonn, Germany. Christian.bode@ukbonn.de. 6. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 7. Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany. 8. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. 9. Department of Haematology, Haemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) support in acute respiratory failure may be lifesaving, but bleeding and thromboembolic complications are common. The optimal anticoagulation strategy balancing these factors remains to be determined. This retrospective study compared two institutional anticoagulation management strategies focussing on oxygenator changes and both bleeding and thromboembolic events. METHODS: We conducted a retrospective observational cohort study between 04/2015 and 02/2020 in two ECMO referral centres in Germany in patients receiving veno-venous (VV)-ECMO support for acute respiratory failure for > 24 h. One centre routinely applied low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35-40 s and the other routinely used a high-dose therapeutic heparinization strategy aiming for an activated clotting time (ACT) of 140-180 s. We assessed number of and time to ECMO oxygenator changes, 15-day freedom from oxygenator change, major bleeding events, thromboembolic events, 30-day ICU mortality, activated clotting time and partial thromboplastin time and administration of blood products. Primary outcome was the occurrence of oxygenator changes depending on heparinization strategy; main secondary outcomes were the occurrence of severe bleeding events and occurrence of thromboembolic events. The transfusion strategy was more liberal in the low-dose centre. RESULTS: Of 375 screened patients receiving VV-ECMO support, 218 were included in the analysis (117 high-dose group; 101 low-dose group). Disease severity measured by SAPS II score was 46 (IQR 36-57) versus 47 (IQR 37-55) and ECMO runtime was 8 (IQR 5-12) versus 11 (IQR 7-17) days (P = 0.003). There were 14 oxygenator changes in the high-dose group versus 48 in the low-dose group. Freedom from oxygenator change at 15 days was 73% versus 55% (adjusted HR 3.34 [95% confidence interval 1.2-9.4]; P = 0.023). Severe bleeding events occurred in 23 (19.7%) versus 14 (13.9%) patients (P = 0.256) and thromboembolic events occurred in 8 (6.8%) versus 19 (19%) patients (P = 0.007). Mortality at 30 days was 33.3% versus 30.7% (P = 0.11). CONCLUSIONS: In this retrospective study, ECMO management with high-dose heparinization was associated with lower rates of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strategy. Prospective, randomized trials are needed to determine the optimal anticoagulation strategy in patients receiving ECMO support.
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) support in acute respiratory failure may be lifesaving, but bleeding and thromboembolic complications are common. The optimal anticoagulation strategy balancing these factors remains to be determined. This retrospective study compared two institutional anticoagulation management strategies focussing on oxygenator changes and both bleeding and thromboembolic events. METHODS: We conducted a retrospective observational cohort study between 04/2015 and 02/2020 in two ECMO referral centres in Germany in patients receiving veno-venous (VV)-ECMO support for acute respiratory failure for > 24 h. One centre routinely applied low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35-40 s and the other routinely used a high-dose therapeutic heparinization strategy aiming for an activated clotting time (ACT) of 140-180 s. We assessed number of and time to ECMO oxygenator changes, 15-day freedom from oxygenator change, major bleeding events, thromboembolic events, 30-day ICU mortality, activated clotting time and partial thromboplastin time and administration of blood products. Primary outcome was the occurrence of oxygenator changes depending on heparinization strategy; main secondary outcomes were the occurrence of severe bleeding events and occurrence of thromboembolic events. The transfusion strategy was more liberal in the low-dose centre. RESULTS: Of 375 screened patients receiving VV-ECMO support, 218 were included in the analysis (117 high-dose group; 101 low-dose group). Disease severity measured by SAPS II score was 46 (IQR 36-57) versus 47 (IQR 37-55) and ECMO runtime was 8 (IQR 5-12) versus 11 (IQR 7-17) days (P = 0.003). There were 14 oxygenator changes in the high-dose group versus 48 in the low-dose group. Freedom from oxygenator change at 15 days was 73% versus 55% (adjusted HR 3.34 [95% confidence interval 1.2-9.4]; P = 0.023). Severe bleeding events occurred in 23 (19.7%) versus 14 (13.9%) patients (P = 0.256) and thromboembolic events occurred in 8 (6.8%) versus 19 (19%) patients (P = 0.007). Mortality at 30 days was 33.3% versus 30.7% (P = 0.11). CONCLUSIONS: In this retrospective study, ECMO management with high-dose heparinization was associated with lower rates of oxygenator changes and thromboembolic events when compared to a low-dose heparinization strategy. Prospective, randomized trials are needed to determine the optimal anticoagulation strategy in patients receiving ECMO support.
Authors: Chitaru Kurihara; James M Walter; Azad Karim; Sanket Thakkar; Mark Saine; David D Odell; Samuel Kim; Rade Tomic; Richard G Wunderink; G R Scott Budinger; Ankit Bharat Journal: Ann Thorac Surg Date: 2020-03-12 Impact factor: 4.330
Authors: Benjamin Seeliger; Pedro David Wendel-Garcia; Klaus Stahl; Christian Bode; Sascha David Journal: Intensive Care Med Date: 2022-02-10 Impact factor: 41.787
Authors: Ruslan Natanov; Elena R Kunkel; Olaf Wiesner; Axel Haverich; Bettina Wiegmann; Stefan Rümke; Christian Kühn Journal: Perfusion Date: 2022-07-04 Impact factor: 1.581
Authors: Marion Wiegele; Daniel Laxar; Eva Schaden; Andreas Baierl; Mathias Maleczek; Paul Knöbl; Martina Hermann; Alexander Hermann; Christian Zauner; Johannes Gratz Journal: Front Med (Lausanne) Date: 2022-07-11